ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 12.5% on Friday . The company traded as high as GBX 4.50 and last traded at GBX 4.50. Approximately 660,701 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 2,689,021 shares. The stock had previously closed at GBX 4.
ImmuPharma Trading Up 12.5%
The stock has a market cap of £28.08 million, a P/E ratio of -12.16 and a beta of 3.02. The business’s fifty day simple moving average is GBX 4.21 and its 200 day simple moving average is GBX 5.38.
ImmuPharma (LON:IMM – Get Free Report) last announced its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. On average, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
